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The 20th century has seen an explosion in medical knowl-
edge, spurred by advances in science and new technology,
resulting in better diagnostic methods and treatment ad-
vances. The outcome has been to extend life and improve
quality of life for people, particularly those with heart
disease. Life expectancy at birth is now approaching 77
years, from less than 70 years of age in 1960, and less than
50 years in 1900 (1). The value of advances in medicine is
evidenced by the growth in medical care services from less
than 6% of the U.S. economy in 1960 to 14% of the gross
domestic product (GDP), now exceeding $1 trillion a year
(1).
The success of advances in the diagnosis and treatment of
heart and vascular disease is reflected in part by declining
overall mortality for acute myocardial infarction and other
diseases of the heart. Even so, heart disease remains the
leading cause of death for Americans and other people
around the world (1). However, because of demographic
changes and the ability to treat previously fatal conditions,
absolute numbers of people living with cardiovascular dis-
ease will increase in the near future (2). The cost-related
impact of these changes is examined in this report.
Expected advances in prevention and treatment technol-
ogies are exciting and promise to further reduce heart
disease–related mortality and morbidity. In this report, we
examine the cost impact of possible future scenarios. En-
thusiasm must be tempered, however, by the knowledge
that life is limited and there will be competing causes of
death, including cancers, Alzheimer’s disease, and other
diseases. Our examination of the current and future cost of
heart disease is limited to direct medical care cost, including
the cost of services related to prevention, diagnosis, treat-
ment, and rehabilitation of people with heart disease. No
estimates will be made regarding the substantial indirect
cost of heart disease to society, including the cost of lost
opportunities related to disability and premature death from
heart disease.
Using three scenarios of the future, we examine potential
cost implications of some future advances in cardiac sciences
in 2010 and 2025. We have chosen to estimate future cost
using three different scenarios to simplify assumptions and
decrease confounding information. We recognize that these
models are based on assumptions and that the most likely
future reality will include some aspects of all the scenarios.
Scenario 1 describes the demographic changes facing the
U.S. The average age of the U.S. population is increasing,
and the percentage of the population over age 65 is growing
rapidly. Because the prevalence of heart disease increases
with age, as do health care utilization and cost, aging alone
will contribute to a substantial increase in cost. The impact
of demographic and other factors is calculated using 1999
data.
Scenario 2 examines the potential impact of advances in
prevention that might lead to new drugs or gene therapies
for preventing atherosclerosis and coronary artery disease
(CAD). These would complement or replace current med-
ications used to control diabetes, obesity, high blood pres-
sure, and high cholesterol, thereby preventing heart attacks,
strokes, and renal failure. These projections also are based
on 1999 data.
Scenario 3 examines the potential impact of improve-
ments in treatment, including new drugs to treat heart
failure and widely available heart transplantation, which
would rely more heavily on swine hearts.
The three scenarios then are combined to provide an
estimate of the combined effects of demographic changes
and improvements in prevention and treatment in 2010 and
2025.
METHODOLOGY
Our methods for projecting the future cost of heart disease
are based on the most recently available cost data, projecting
costs to 1999 so that it can be used as the base year. Future
cost increases or decreases in 2010 and 2025 are projected,
using 1999 dollars and ignoring the effects of future infla-
tion in prices.
We have chosen to model future costs of heart diseases,
including CAD, congestive heart failure, and part of hyper-
tensive disease, as well as other “heart” diseases. Using the
ICD-9 CM disease classification, our analysis included
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Excluded are congenital anomalies of the heart, symptoms
that might involve the cardiovascular system, and renal and
pulmonary sequelae.
In some cases, it is not possible to obtain information on
utilization and cost of heart disease alone, but information is
available on all cardiovascular diseases, including heart
disease, hypertensive disease, and cerebrovascular disease.
When possible, cost information is provided on all cardio-
vascular diseases as well as heart disease alone; heart disease
accounts for 60% of the cost of all cardiovascular disease
(3,4).
Our work builds directly on the work of Hodgson and
Cohen (3), who took the total health care cost in 1995 and
identified the proportion represented by all cardiovascular
diseases (16.9%) and by heart disease alone (10%). The
projections made by the American Heart Association for
1999 (4) use the work of Hodgson and Cohen to predict
1999 cost for heart disease and for all cardiovascular
diseases.
To simplify the comparison of costs over time, all future
costs are stated in terms of 1999 dollars. This simplification
holds the value of the dollar constant, ignoring any future
effects of inflation on the value of a dollar and on total
health care cost. In the calculation of the cost-effectiveness
of prevention (scenario 2), future cost is discounted at the
rate of 3% per year to estimate present value.
A generally accepted measure of effectiveness or benefits
from a life-saving medical intervention is the number of
quality-adjusted life years (QALYs) added to the patient’s
life. The QALY is the number of years added to life,
including an adjustment to take into account the extent of
disability, pain, or other limitations. This adjustment can be
made using patient utilities for different health states; for
example, one year of additional life with angina (without
congestive heart failure) is equivalent to 0.84 QALYs (5).
Our scenarios will use QALYs to calculate the cost of
preventive interventions per QALY.
Various costs of care are estimated for major categories of
service, including hospital (inpatient and outpatient), phy-
sician, nursing home, drugs, home health, and other health
care costs using national data sources (6). Costs include all
services paid for by Medicare, Medicaid, and private insur-
ance, as well as out-of-pocket expenditures paid by patients.
The overall contribution of circulatory system disease to
total U.S. health care expenditures is discussed.
RESULTS
Total U.S. Health Care Expenditures
The U.S. health care system is the most expensive in the
world. The U.S. spent over 14% of its GDP, or one in every
seven dollars, on health care in 1998. Total health care
expenditures are approximately $1 trillion, divided among
the following: hospital care, 38%; physician services, 22%;
other professional and dental services, 12%; drugs, 11%;
nursing home and home health care, 12%; and other costs,
5% (Fig. 1). The fastest growing category is drugs, whereas
the growth in home health care has slowed, and expendi-
tures for hospital and physician services now account for a
smaller proportion of total costs than they did in 1990 (6).
Hospital expenditures declined from 42% of total health
care expenditures in 1990 to 38% by 1997, and physician
expenditures declined from 24% in 1990 to 22% by 1997.
Expenditures for Heart Disease
Extrapolating forward to 1999, total U.S. health care
expenditures are expected to be $1,059 billion, of which
$178 billion (16.8%) will be for all cardiovascular diseases
and $102 billion (9.6%) will be for heart disease alone (4).
Hospital care, including inpatient medications, is expected
to account for 60% of the cost of heart disease, and the
remaining 40% breaks down as follows: 13% for physician
services, 7% for outpatient drugs, 4% for home health care,
and 16% for nursing home care (Fig. 2).
Hospital Services
Inpatient services. The most recent hospitalization data
show that there were 6.1 million discharges for all cardio-
vascular diseases, representing 19.7% of the 30.9 million
Figure 1. Distribution of total U.S. health care expenditures by
type of service (HCFA 1999).
Figure 2. Distribution of U.S. health care expenditures for heart
diseases by type of service, 1999 estimates (AHA 1998).
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hospital discharges in 1997. Heart disease accounted for 4.2
million discharges, or 13.6% of all hospital discharges,
occurring at the rate of 1,550 discharges per 100,000
population (7). Americans received 5.4 million inpatient
cardiovascular procedures, with some of the frequent cardiac
procedures being coronary artery bypass graft (CABG)
surgeries on 366,000 patients, 1.1 million cardiac catheter-
izations, and 317,000 pacemaker insertions or replacements.
As would be expected, cardiovascular procedure rates were
highest among patients age 65 and older (8,608 per
100,000), and the number of procedures declines with
younger age (3,297 for ages 45–64, and less than 50 per
100,000 for patients under 45 years).
Ambulatory surgery. Operative and diagnostic procedures
are being done more frequently on an outpatient basis and
no longer require hospitalization, even though most ambu-
latory surgery is done in a hospital facility. In 1996, 898,000
(2.9%) of the 31.5 million procedures done in ambulatory
settings, or 340 per 100,000 persons, were operations on the
cardiovascular system (8). The most frequently performed
cardiac procedure was catheterization, which accounted for
472,000 (52.6%) of these procedures. Adding together
inpatient and ambulatory catheterization procedures, the
total was 1.57 million in 1997, or an overall rate of 600 per
100,000.
Emergency and outpatient department services. In 1997,
4.5 million patient visits (4.7% of all visits) to hospital
emergency departments were diagnosed as cardiovascular
disease (9). This figure represents 1,700 visits per 100,000
people per year. In addition, there were 77 million visits to
hospital outpatient departments in 1997. Cardiovascular
disease accounted for 4.8 million of the 77 million visits
(6.6%), or 1,800 visits per 100,000 people per year. One of
the most commonly occurring diagnoses was essential hy-
pertension (3.1 million visits), which accounted for a ma-
jority of all cardiovascular disease visits (10).
Projected 1999 expenditures for hospital services. Pro-
jecting expenditures from 1997 to 1999, hospital costs are
expected to be $60.3 billion for heart disease and $89.2
billion for all cardiovascular disease. Total U.S. hospital
costs in 1999 are expected to be $395 billion, of which
cardiovascular disease will comprise 22.6%, including 15.3%
for heart disease.
Physician Services
Statistics are available for physician office-based services; no
comparable data are available for inpatient physician services
in the U.S. In 1997, there were 787 million office visits to
physicians (11). Including all physician specialties, the
primary diagnosis for 80.2 million physician visits was
cardiovascular disease, representing 10.2% of all physician
office visits, or 30,000 per 100,000 people. These diagnoses
included 29.7 million visits (3.5%) for hypertension; 10.7
million (1.4%) for ischemic heart disease; and 9.2 million
(1.2%) for other heart diseases, excluding ischemia. Physi-
cians identifying themselves as cardiovascular specialists
reported 17.3 million visits, or 2.2% of the 787 million
physician visits, representing 6,500 visits per 100,000 peo-
ple. Drugs were prescribed during 83% of these visits, with
an average of 4.6 drugs prescribed per visit.
Projected 1999 physician expenditures for all cardiovas-
cular disease are $26.8 billion; for heart disease alone,
expenditures total $13.8 billion (4). Total physician expen-
ditures are expected to be $233 billion in 1999, with 11.5%
for all cardiovascular disease and 5.9% for heart disease.
Prescription Drugs
Prescription drug cost is rising more rapidly than other
health expenditure. In 1999, outpatient prescription cost
was expected to be $6.6 billion for heart disease (6.5% of
total heart disease cost) and $16 billion for all cardiovascular
disease, accounting for 9% of all cardiovascular disease costs
(4). As a percentage of total 1999 U.S. health care expen-
ditures, outpatient heart disease drugs represent 0.6%, and
all cardiovascular disease drugs account for 1.6%.
Nursing Homes and Home Health
In 1995, 1.39 million Americans were nursing home resi-
dents (7). A primary diagnosis of cardiovascular disease was
given to 27.1% of these individuals, including 10.9% with
heart disease, 2.4% with cerebrovascular disease, and 3.6%
with essential hypertension. Projecting to 1999, nursing
home cost for heart disease is expected to be $16.1 billion,
and nursing home cost for all cardiovascular disease will
likely be $35.1 billion. Total nursing home cost is expected
to be $90.1 billion in 1999, with 39% being spent on all
cardiovascular disease and 17.9% on heart disease.
In 1996, 2.5 million patients were using home health or
hospice services, with a total of 8.2 million discharges from
care occurring during the year (12). Classifying the 2.5
million patients by primary diagnosis reveals that 623,000
(25%) had cardiovascular disease, with 268,000 (10.8%)
having heart disease and 108,000 (4.3%) having essential
hypertension. Projected 1999 home health expenditures for
heart disease are $4.0 billion, and $8.9 billion for all
circulatory diseases.
Trends in Utilization
The growth in cardiovascular procedure volumes has been
substantial over the past two decades. While volume for
many procedures has doubled or tripled during this time
period, hospitalization for cardiovascular disease has grown
modestly. In 1979, there were approximately five million
discharges with a principal diagnosis (first listed) of cardio-
vascular disease; by 1997, this number had increased only
20% to 6.1 million. The same trends occurred for CAD
discharges and stroke. By contrast, discharges for congestive
heart failure have approximately doubled from 1979 to
1997, totaling more than 900,000 in 1997 (4).
Hospitalizations have not increased as much as proce-
dural volumes, partially because of the movement of proce-
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dures to ambulatory care settings. In 1996, 898,000 ambu-
latory procedures were performed on the cardiovascular
system, and there were more than five million inpatient
procedures. One of the high-volume procedures is cardiac
catheterization, with 1.1 million inpatient procedures done
in 1997. The most recent data available (1996) indicate that
an additional 472,000 procedures were done in ambulatory
surgery settings for a total number of catheterizations at
more than 1.5 million procedures. This estimate represents
an overall growth in cardiac catheterization procedures since
1979 of greater than 315% (4). In 1997, 366,000 patients
underwent CABG surgery, representing an increase of more
than 228% since 1979. Similar trends were noted for heart
transplantation. In 1997, 2,290 heart transplants were per-
formed in the 275 U.S. transplant centers, compared with
57 in 1980. The numbers of transplants performed continue
to fall far short of the estimated requirement of 40,000
among those age 65 and younger (12,4). Growth in proce-
dure rates is expected to continue to grow faster than
hospital discharges in the near future.
1999 Heart Disease Costs: Summary and Limitations
Resources spent on services to prevent, diagnose, treat, or
rehabilitate individuals with heart disease were expected to
be $102 billion in 1999, accounting for approximately 10%
of total U.S. health care expenditures. The majority were for
hospital care (60%), followed by nursing home (16%) and
physician services (13%), as shown in Figure 2. Cardiovas-
cular procedures are being done more often in ambulatory
surgery settings, most of which are hospital based. Other
factors contributing to changes in the diagnostic mix of
heart-disease patients admitted to hospitals include mortal-
ity trends. In particular, as the mortality rate for acute
myocardial infarction has declined in recent years, there has
been a growth in admissions for congestive heart failure. As
a result there is greater demand for heart transplants,
currently the most costly heart disease intervention. The
high cost is not primarily from the complexity of the
procedure or physician charges but instead is from drug
costs and long hospital stays.
Our estimates of the future cost of heart disease were
based on the 1999 cost of heart disease. The national
averages used mask substantial variability in practice by
geographic region. Several factors contribute to these vari-
ations, including geographic differences in the availability of
services, differences in ability to pay and insurance coverage,
and differences in physician practice patterns (13–15). One
concern is that not all needs for cardiovascular care are
currently being met. To the extent that the current health
care system is failing to meet needs, our estimates of future
use and cost of heart disease care will be understated.
Scenario 1: Impact of Population Changes
Scenario. The growth and aging of the U.S. population is
expected to contribute to increased cost for the care of heart
disease. In Table 1, Foot (2) estimates that the prevalence of
heart disease (16.4% of the U.S. population in 2000) will
change relatively little in 10 years (15.6%) and in 25 years
(16.8%). However, because of a growing population, the
number of people with heart disease is expected to increase
from 23.4 million in 2000 to 27.1 million in 2010 and 34.2
million in 2025.
Assumptions and calculations. The estimated cost of
heart disease in 1999 is $101.8 billion, including hospital,
physician, drug, nursing home, and other health care costs.
This cost equals approximately $4,350 per person with heart
disease. Projecting the per-person cost to 2010 and 2025
results in total costs of $118 billion and $149 billion,
respectively. These projections assume the same rates of
diagnosis and treatment, and use of the same technologies as
today. This calculation provides an estimate of the cost
impact of demographic changes alone, including some
increase in overall longevity, but no heart disease–specific
changes in mortality.
Impact on costs. Demographic changes will lead to a 15%
increase in expenditures for heart disease treatment by 2010
and a 46% increase by 2025, as measured in 1999 dollars.
Scenario 2: Impact of Improvements
in Prevention of Cardiovascular Disease
Scenario. Let us assume that there are new “magic-bullet”
drugs or nutriceuticals available by 2010 that can be taken by
those with risk factors to prevent atherosclerosis and CAD.
The drug cost is high, estimated to be $250 per month or
approximately $8 per day in 1999 dollars. Future savings
would be expected to occur because of the reduction in acute
myocardial infarction and invasive treatments for CAD. By
2010, there would be little impact, but by 2025 the
prevalence of CAD will have declined by 25%. Prevention
of CAD is expected to add an average of two QALYs for
people without CAD.
Table 1. Estimated U.S. Population Age Distribution and Prevalence of Heart Disease: 1990–
2025 (2)
Percent of U.S.
Population Age 651
Prevalence
of Heart
Disease
Heart Disease
Prevalence (millions)
Percent Males
With Heart
Disease
2000 12.6% 16.4% 23.4 49.9%
2010 13.2% 15.6% 27.1 51.1%
2025 18.3% 16.8% 34.3 52.2%
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Assumptions and calculations. Currently 50% of people
with heart disease have atherosclerotic disease. We assume
the preventive drug or drugs will be taken by 50% of those
who would be expected to benefit, and about 25% of
ischemic disease and its costs will be prevented by 2025.
Coronary artery disease (ICD-9: 410–414) affects ap-
proximately half of those with heart disease and accounts for
51% of the total heart disease cost, estimated to be $51.9
billion in 1999 and $75.8 billion in 2025 if no preventive
drugs are available. The potential is to save at least a quarter
of this amount, or $19 billion, in 2025 with prevention.
Among patients with CAD (estimated to be 17.2 million
people or 8.4% of the population), we assume that half (8.6
million or 4.2% of the population) will take the drug
regularly, and for one quarter (4.3 million or 2.1%) the
disease will be prevented and cost of treatment saved. The
cost of the drug or drugs for 8.6 million people would be
$25.8 billion annually. Other costs would include periodic
physician visits, which many of these individuals would
already have. Before 2025, we assume, drug costs would be
incurred for 15 years before any substantial savings would be
achieved through prevention of subsequent CAD.
Cost impact. In 2010, an additional $25.8 billion a year
will be spent for the preventive drug or drugs, adding 22%
to heart-disease expenditures that year. No savings are
expected before 2025, when CAD expenditures would be
reduced by $19 billion because of prevention, but the
continuing medication cost of $25.8 billion annually results
in a net increase in cost of $6.8 billion in 2025. This figure
represents an overall increase in 2025 heart-disease cost of
5%. If the cost of drugs is 50% lower than projected ($4 a
day or $125 a month), there will be a net savings in 2025 of
$6.1 billion or 4% of 2025 projected heart disease cost.
However, if the cost of drugs is 50% higher, then overall
cost would increase $19.7 billion, adding 13% to 2025 costs.
Cost-effectiveness. The preventive drug is assumed to be
taken starting in 2010 for 15 years before the expected onset
of CAD and for the next 10 years of life, adding two good
years of life for 25% of the people who would have
developed CAD. Future cost would be discounted at the
rate of 3% per year.
The cost per QALY from prevention would be $41,000.
If the cost of drugs is 50% lower ($4 a day), then the cost per
QALY would decrease to $14,500, whereas a 50% increase
in the cost of drugs ($12 a day) would increase the cost per
QALY to $68,000.
Scenario 3: Impact of
Improvements in Treatment Technologies
Scenario 3A. Suppose medications that reverse heart fail-
ure become available by 2010, and by 2025 these drugs have
reduced hospitalizations for congestive heart failure. As-
suming that the cost of medication is $250 a month or
approximately $8 a day in 1999 dollars and there is 50%
compliance, the potential savings could be 40% of conges-
tive heart failure hospital cost. Physician charges and other
costs would be expected to remain about the same.
Assumptions and calculations. If no changes in treatment
occur by 2025, hospital costs for congestive heart failure are
expected to be 11.3% of the total heart disease cost of $149
billion. Taking 40% of the $16.8 billion congestive heart
failure hospital cost provides an estimate of $6.7 billion in
potential savings. To estimate the cost of the new drug,
assume that approximately 20% of people with heart disease
who have congestive heart failure, or 6.8 million people,
would be treated in 2025. Assuming 50% compliance with
the full prescription, the drug cost would be $10.2 billion in
2025.
Cost impact. In 2025, treatment of congestive heart failure
will increase costs by $3.5 billion, adding 2% to the total
projected heart disease cost. If the cost of drugs is 50% lower
($4 a day), then there will be a net savings of $1.6 billion; a
50% increase in the cost of drugs ($12 a day) would lead to
an overall increase of $8.6 billion in the cost of heart disease.
Scenario 3B. Assume that by 2010, swine heart transplan-
tation has become common at roughly half the cost of a
human transplant and that by 2025, the use of organs from
swine has surged from a few thousand in 2010 to approxi-
mately 58,000 transplants a year, meeting the full demand.
Assumptions and calculations. Assume transplant costs
average $150,000 per transplant, plus $10,000 per year for
ongoing medical management. This estimate is somewhat
more than half of the 1996 costs reported: $253,000 in the
first year, with annual follow-up costs of $21,200 per year
(12). In 1996, it was estimated that 40,000 people, or about
1,700 per 100,000 people with heart disease, needed re-
placement hearts each year, but only 5% of those needing a
transplant received one. By 2025, it is assumed that all
patients who need a transplant will have one, which will
represent about 58,000 transplants a year at that time.
Assuming that people live an average of 10 years with a
transplanted heart, there will be approximately 522,000 who
will need ongoing medical management. The estimated
annual costs for transplantation will be $8.7 billion in 1999
dollars, and the annual medical management cost will be
$5.2 billion, totaling $13.9 billion. Assume that this aggres-
sive heart transplant program reduces the total cost of
treating congestive heart failure by 50%. Congestive heart
failure represents 18.7% of all heart disease costs, projected
to total $149 billion in 2025. The savings would be 9.35%
of the $149 billion of all heart disease costs, or $13.9 billion
in 2025.
Cost impact. In 2025, the cost of heart transplants will
equal the cost savings expected to be achieved by an
expected 50% reduction in total expenditures for congestive
heart failure. If reductions in congestive heart failure expen-
ditures were to be greater than 50%, then there would be a
net savings; less than 50% reductions would increase costs
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over savings. However, if the cost of heart transplants does
not decline by 50%, as predicted, then the additional cost
would be $14.5 billion at current value (1999 dollars),
adding 9.7% to total heart disease costs in 2025.
Combined Scenarios for Demographic
Changes, Prevention, and Treatment
Scenario. The future is likely to represent the combined
effects of demographic changes (Scenario 1), possible ad-
vances in the prevention of atherosclerosis and CAD (Sce-
nario 2), and possible advances in the treatment of heart
failure and heart transplantation (Scenario 3).
Assumptions and calculations. Assuming that a 25% re-
duction in CAD is achieved by 2025 (Scenario 2), for
purposes of cost calculations we assume that this reduction
will lead to a 50% reduction in congestive heart failure and
a 50% reduction in the need for heart transplants.
In 2010, demographic changes will have increased the
numbers of people with heart disease by 15%, and expen-
ditures will have increased by $16 billion. The new CAD
preventive drug is assumed to have been introduced in 2010,
adding $25.9 billion (1999 dollars) to costs without sub-
stantially reducing the cost of treating CAD until 2025.
By 2025, demographic changes will have further in-
creased the numbers of people with heart disease by 46%,
increasing heart disease cost by $47 billion over the 1999
amount. Also, by 2025, benefits from the prevention of
CAD will contribute to a reduction in the cost of treatment
of $19 billion, partially offsetting the continuing preventive
drug cost of $25.8 billion annually. As a result of the
effectiveness of CAD prevention, there will have been a 50%
reduction in congestive heart failure and the need for heart
transplants, which will reduce the cost of drugs for reversing
heart failure to $5.1 billion (assuming 50% compliance),
providing a savings of $6.7 billion in reduced hospitaliza-
tions but leading to a $1.6 billion net increase in cost. The
estimated need for heart transplants is 29,000 in 2025 at an
estimated annual cost of $4.4 billion, plus an annual medical
management cost of $2.6 billion, totaling $7.0 billion. This
equals the projected savings from reduced hospitalizations
for congestive heart failure.
Cost impact. In 2010, heart-disease costs will have in-
creased because of demographic changes and the introduc-
tion of a preventive treatments, totaling $143.9 billion or an
increase of 41% over the $102 billion spent in 1999. By
2025, there will be further increases in heart disease cost
because of continuing demographic changes, combined with
costs and projected savings from preventive treatment of
coronary artery disease, new drugs to reverse heart failure, and
advances in heart transplants, totaling $157.5 billion in the cost
of heart disease, or a 54% increase over the 1999 cost.
Limitations
The crystal ball that we have used to predict the future is
built on a foundation of current physician, hospital, and
nursing home practices, their costs, and the products emerg-
ing from research that hold promise for prevention and
better treatments. The opportunity for error in cost predic-
tions is large, even though we think predicting future heart
disease treatments that will be used in practice over the next
10–25 years is not unreasonable. The greater confidence in
the latter is based on the lag between when new knowledge
becomes available and when it becomes useful and practical
to provide it to patients across the U.S.
Other potential biases that should be recognized include
reductions in inpatient care and the growth of outpatient
services that hold the promise of reducing cost. Also, as new
techniques are developed, some will save costs, particularly if
they are less invasive and require shorter recovery periods.
At the same time, individuals with congenital heart diseases
are living longer, and their need for care can be expected to
increase as the number of adults increases. There may be
other treatment successes that will add to costs as we add
years to people’s lives. These possibilities are not explicitly
taken into account in this report, nor are potential cost
savings from changes in service delivery.
DISCUSSION
Our aging population is driving costs for heart disease care
higher and higher. Expenditures for heart disease increase
with age; average cost of heart diseases is more than four
times higher for people over age 75 than for those under age
65. Although cardiovascular disease accounts for almost
17% of all health expenditures, this proportion doubles for
people age 85 and older to 35% (3). We need to consider
priorities for prevention versus treatment and rehabilitation
and how to pay for preventive and curative care. In doing so,
we need to examine cost and effectiveness carefully, taking
into account that we may need to incur preventive care costs
early to obtain benefits that may be delayed many years.
This work represents an initial effort to examine specific
scenarios and estimate their potential impact on future costs
of heart disease in the U.S. (Fig. 3).
Prevention is almost always preferred over the suffering of
heart disease and its treatment sequelae; however, current
prevention technologies are not being used fully. Slightly
more than half of all Americans with hypertension are
receiving treatment, but only approximately half of these
people have their blood pressure under control (1). Those at
risk must be identified and must adopt the preventive
treatments and health behaviors. Once these preventive
strategies are adopted, these patients must adhere to the
preventive regimen over time, possibly decades. Experience
suggests that many will not adopt or adhere over time.
Another consideration is cost. The number of people with
the target risk factor—for example, hypercholesterolemia—
will far exceed the number of people who will develop the
target condition. Cost-effectiveness analysis is one method
for comparing the costs of preventive services over time with
the benefits (added years of life), which may not occur until
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years later. Scenario 2 predicts a new drug to prevent
coronary heart disease, which would extend life at an
average cost of $41,000 per QALY.
Other opportunities for prevention may come from
screening for genetic risks at birth and providing people
with individualized risk profiles by 2025. For some people,
reduction of alcohol, changes in diet, and routine exercise
may be more important to heart health than for others. Our
current risk information provides average risks by age,
gender, and comorbidity, not by individual, genetically
specific risks, something we may be able to provide in the
future. Individuals may still find it hard to adopt all
heart-healthy behaviors, but they may be more highly
motivated by knowledge of their own genetic susceptibilities
and risks.
Diagnosis and treatment of heart disease are likely to
remain the major foci of cardiovascular medicine and will
incur a majority of heart disease costs until 2025. Scenario 3
includes two possibilities, a new medication to reverse heart
failure and the availability of swine hearts for heart trans-
plantation. The predicted $3.5 billion net cost of reversing
heart failure is probably reasonable, whereas, the projection
of no increase in cost for heart transplants may be overly
optimistic. It is important to remember that, historically,
advances in treatment generally have not been less expensive
than current treatments. Even if our predictions are opti-
mistic, one can be confident that there will be demand for
advances in treatment that may add to years of life and
maintain a high level of functioning throughout these years.
Financing heart disease care into the next century will be
an important and difficult challenge. As noted previously,
current financing of health care is not meeting the needs of
all Americans. Individuals who are poor, uninsured, and
from minority populations are not enjoying the full benefits
of the preventive and therapeutic services we have available
today. Ensuring access to high-quality care would increase
the current costs of the health care system, possibly by 10%.
Even among people who are insured, it is estimated that not
all of the needs of heart disease patients are being met.
What it would cost to meet all of these needs is uncertain,
but one might guess that it could add 10%–30% to costs.
Adding this sum to our combined-scenario estimate of a
54% cost increase by 2025, including demographic changes,
plus advances in prevention and treatment, we might expect
the total heart disease cost to rise as much as 64%–84%
assuming we can find a way to pay for this additional cost.
How do we finance these increases? The federal and state
governments’ shares of health care expenditures continue to
increase. In 1997, total health care expenditures were $969
billion, of which government paid 45%, private insurance
paid 32%, and the remainder was mainly paid out of pocket
(6). The government share will rise as the population ages
and a higher proportion of citizens are over age 65 and
receiving Medicare. Extrapolating from 1972 and 1997,
when the government paid 41% and 45% of all costs,
respectively, one could expect the government share to
exceed 50% by 2010. Out-of-pocket costs are increasing as
employers have shifted more of the costs of health benefits
to the employees. By 2010, we can expect the percentage
paid by private insurance to have declined, possibly to below
30%, and the portion paid out of pocket to be rising. These
trends can be expected to lead to tighter cost controls over
the use of government dollars. Increases in out-of-pocket
payments can be expected to reduce the number of people
who can afford health insurance as well as the access to care
for people with lower incomes, where expenditures on
health care compete with housing, transportation, and food
costs.
What are reasonable options for the future financing of
preventive and curative treatments for heart disease? One
positive scenario would be sufficient growth in GDP that we
could accommodate increases in heart disease costs without
increasing the proportion of GDP dedicated to health care,
now at 14%. The GDP would have to increase in real terms
by 64%–84% by 2025, assuming that all other health care
costs were increasing at the same rate as heart disease costs.
Another possibility is that heart disease cost will be increas-
ing at a faster rate than total health care cost in the future.
This change may occur if people perceive the benefits of
heart disease intervention and treatment to be greater than
treatments for other diseases or if factors driving costs of
other diseases are less intense than factors driving costs of
heart disease. If this change occurs, then the proportion of
total health care cost expended on heart disease will rise
above its current level of approximately 10%.
Among the challenges of the new millennium will be to
find creative and innovative ways to provide more efficient
and more effective care to the growing number of people
with heart disease. If we can meet this challenge, then the
full range of new and exciting prevention and treatment
technologies should be available to all Americans. If we fail,
then many Americans will never be able to afford and
benefit from the scientific miracles to come.
Figure 3. Project costs of scenarios 1, 2, 3, and combined scenarios
in 2010 and 2025.
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